Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Melanoma and other skin tumours

1989 - Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)

Date

28 Sep 2019

Session

Poster Discussion – Melanoma and other skin tumours

Presenters

Henrik Jespersen

Citation

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Authors

H. Jespersen1, R. Olofsson Bagge2, G. Ullenhag3, A. Carneiro4, H. Helgadottir5, I. Ljuslinder6, M. Levin1, C. All-Eriksson7, B. Andersson8, U. Stierner1, L.M. Nilsson9, J.A. Nilsson9, L. Ny1

Author affiliations

  • 1 Department Of Oncology, Sahlgrenska University Hospital, 413 45 - Gothenburg/SE
  • 2 Sahlgrenska Academy, University of Gothenburg - The Sahlgrenska Academy, 405 30 - Göteborg/SE
  • 3 Oncology, University Hospital Uppsala Akademiska Sjukhuset, 751 85 - Uppsala/SE
  • 4 Oncology And Radiation Physics, Skane University Hospital, 222 41 - Lund/SE
  • 5 Department Of Oncology, Karolinska University Hospital, 171 76 - Stockholm/SE
  • 6 Department Of Oncology, Norrlands University Hospital, 901 85 - Umeå/SE
  • 7 Department Of Oncology, St. Erik Eye Hospital, 112 30 - Stockholm/SE
  • 8 Department Of Clinical Immunology And Transfusion Medicine, Sahlgrenska University Hospital, 413 45 - Gothenburg/SE
  • 9 Surgery, University of Gothenburg - The Sahlgrenska Academy, 405 30 - Göteborg/SE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1989

Background

While recent years have seen a revolution in the treatment of metastatic cutaneous melanoma, no treatment has yet been able to demonstrate any prolonged survival in patients with metastatic uveal melanoma. Reports of treatment with immune checkpoint inhibitors in monotherapy have been disappointing. There is preclinical evidence that the effect of immunotherapy may be augmented by epigenetic therapy through mechanisms including enhanced expression of HLA class I and cancer antigens, and suppression of myeloid suppressor cells.

Methods

We performed a multicenter, open label phase II study assessing the efficacy of concomitant use of the PD-1 inhibitor pembrolizumab and the HDAC inhibitor entinostat in 29 adult patients with metastatic uveal melanoma. Eligible patients had histologically confirmed metastatic uveal melanoma, ECOG performance status 0–1, and measurable disease as per RECIST 1.1. Patients received pembrolizumab 200 mg intravenously every third week in combination with entinostat 5 mg orally once weekly. Primary endpoint was objective response rate (ORR). Secondary endpoints include clinical benefit rate (CBR; CR, PR or SD) at 18 weeks, overall survival (OS), and safety assessed by adverse events (AE).

Results

At the data cut off of June 21, 2019, 29 patients had been enrolled and received at least one dose of treatment with a median follow up of 7.7 months. Ninety per cent had liver metastases and 59% had received previous treatment for metastatic disease. A partial response (PR) was observed in 3 patients resulting in an ORR of 10%. Nine patients (31%) had a best overall response of stable disease (SD). Clinical benefit at week 18 was observed in 7 out of 29 patients (24%). Median OS was 11.5 months. Twenty-eight patients (97%) experienced treatment related AEs, and grade 3-4 AEs were reported in 18 patients (62%). There were no treatment related deaths.

Conclusions

The PEMDAC study has demonstrated that combined HDAC- and PD-1-inhibition can result in clinical efficacy in metastatic uveal melanoma with manageable toxicities. The obtained data warrant further investigation to address clinical and immunological characteristics of patients achieving clinical benefit.

Clinical trial identification

NCT02697630 (Registered 3 March 2016). EudraCT: 2016-002114-50.

Editorial acknowledgement

Legal entity responsible for the study

Sahlgrenska University Hospital, Västra Götaland Region.

Funding

Syndax Pharmaceuticals and Merck & Co. Inc.

Disclosure

R. Olofsson Bagge: Advisory / Consultancy: Merck & Co. Inc. (MSD Sweden). G. Ullenhag: Advisory / Consultancy: Merck & Co. Inc. (MSD Sweden). I. Ljuslinder: Advisory / Consultancy: Merck & Co. Inc. (MSD Sweden). M. Levin: Advisory / Consultancy: Merck & Co. Inc. (MSD Sweden). U. Stierner: Advisory / Consultancy: Merck & Co. Inc. (MSD Sweden). L. Ny: Advisory / Consultancy: Merck & Co. Inc. (MSD Sweden). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.